Treating Male Partners Reduces Recurrence in Bacterial Vaginosis

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on March 10, 2025.

By Elana Gotkine HealthDay Reporter

MONDAY, March 10, 2025 -- Treating male partners in addition to women with bacterial vaginosis results in a lower rate of recurrence than treating only women, according to a study published in the March 6 issue of the New England Journal of Medicine.

Lenka A. Vodstrcil, Ph.D., from the Melbourne Sexual Health Centre at Monash University in Australia, and colleagues conducted an open-label, randomized controlled trial involving monogamous heterosexual couples in which the woman had bacterial vaginosis. In the partner-treatment group, the woman received first-line recommended antimicrobial agents and the male partner received oral and topical antimicrobial treatment (metronidazole 400-mg tablets and 2 percent clindamycin cream applied to penile skin, both twice daily for seven days), while in the control group, the woman received first-line treatment and the male partner received no treatment. Eighty-one and 83 couples were assigned to the partner-treatment and control groups, respectively.

After 150 couples had completed the 12-week follow-up period, the trial was stopped by the data and safety monitoring board because treatment of the woman only was inferior to treatment of both the woman and her male partner. The researchers found that recurrence occurred in 35 and 63 percent of women in the partner-treatment and control groups, respectively, in the modified intention-to-treat population (recurrence rate, 1.6 and 4.2 per person-year, respectively). Adverse events included nausea, headache, and metallic taste in treated men.

"Our trial showed that treating male partners with a week of oral metronidazole and topical clindamycin, together with treatment of women, resulted in a lower rate of recurrence of bacterial vaginosis within 12 weeks than treatment of the woman alone," the authors write.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-03-11 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords